Astellas’ Once-Daily Tacrolimus Gets Nod From Europe’s CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive opinion comes after FDA issued a mix of “approvable” and “not approvable” decisions for three transplant claims.
You may also be interested in...
Astellas Tacrolimus Approval Remains At Bay
On heels of second “approvable” letter for kidney transplant rejection, FDA issues another approvable for liver indication.
Astellas Tacrolimus Approval Remains At Bay
On heels of second “approvable” letter for kidney transplant rejection, FDA issues another approvable for liver indication.
Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients
Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.